Skip to content

A Clinical trial to compare the effect of methotrexate alone and the effect of giving methotrexate along with atorvastatin for the treatment of psoriasis vulgaris

The Efficacy of Methotrexate versus Methotrexate + Atorvastatin in the treatment of chronic plaque type psoriasis - A Randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016101
Enrollment
66
Registered
2018-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: methotrexate (upto 15mg), atorvastatin 20mg: methotrexate 7.5mg to 15mg - per oral route, weekly once for 6 months + atorvastatin 20mg per oral daily for 6 months Control Intervention1:

Sponsors

SRM MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting to the in-patient and out-patient department of dermatology, SRM medical college hospital, Potheri With chronic plaque type psoriasis diagnosed clinically &histopathologically (wherever necessary) by a dermatologist Having PASI score > 12 Patients who are statin naïve

Exclusion criteria

Exclusion criteria: acute or chronic liver disease myopathies family history of hereditary muscular disorders (assessed by history, clinical examination, raised serum alanine aminotransferase and creatinine phophokinase thrice the upper limit) uncontrolled hypertension with known allergy to any of the treatment patients taking any drug that might interact with statins already taking statins impaired renal function or creatinine >2.0 mg/dl active infection or WBC > 10,000/cmm pregnant and lactating females females and males who did not complete their family

Design outcomes

Primary

MeasureTime frame
reduction in PASI score more than or equal to 50% from intial PASITimepoint: 6 months

Secondary

MeasureTime frame
reduction in PASI score more than or equal to 75% from intial PASITimepoint: 9 months

Countries

India

Contacts

Public ContactDHIVYA S

SRM MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE

leecutis@gmail.com9840168711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026